Rubicon Research IPO allotment date today: 5 steps to check status online on MUFG via PAN; issue booked 100x

Rubicon Research IPO Allotment Date : The initial public offering (IPO) of Rubicon Research Limited witnessed an overwhelming response from investors with the issue was concluded with 103.90 times subscription. The IPO received bids for 1,70,96,80,620 shares against 1,64,55,670 shares on offer, reflecting strong investor confidence in the Mumbai-based pharmaceutical formulations company.

The Rubicon Research IPO allotment is set to be finalised today, October 14 with bidders likely to receive allotment status updates by Tuesday. The issue was closed on Monday, October 13.

Rubicon Research IPO: Price band, lot size

The company had fixed the IPO price band at Rs 461–Rs 485 per share, with investors able to bid for a minimum of 30 shares per lot (Rs 14,550).

At the upper price band of Rs 485, Rubicon Research's valuation estimated around Rs 7,990 crore.

The IPO comprises a fresh issue worth Rs 500 crore and an offer-for-sale (OFS) of Rs 877.5 crore by existing shareholders.

Rubicon Research IPO GMP

Rubicon Research IPO last GMP is Rs 127, last updated Oct 14th 2025 05:58 AM. With the price band of 485.00, Rubicon Research IPO's estimated listing price is ₹612 (cap price + today's GMP).The expected percentage gain/loss per share is 26.19%

According to websited that track unlisted market space information, Rubicon Research shares were commanding a grey market premium (GMP) of Rs 127 on Tuesday morning. This suggests that the stock could list at around Rs 612 per share, a 26 per cent premium over the issue price.

Important dates

BRLMs

The IPO is being managed by Axis Capital, IIFL Capital Services, JM Financial, and SBI Capital Markets, while MUFG Intime India Pvt. Ltd. is the registrar to the issue.

Here is a step-by-step guide to check your allotment status after finalisation via registrar’s website (MUFG – Link Intime)

About Rubicon Research

Rubicon Research Limited is a pharmaceutical formulations company focused on research-driven innovation, specialising in speciality and drug–device combination products. The firm primarily caters to regulated markets such as the United States, which accounts for a major share of its revenue.

Between FY2023 and FY2025, the company recorded an impressive revenue CAGR of 75.89 per cent, nearly seven times the industry average, cementing its position among India’s fastest-growing formulation companies. In FY2025 alone, Rubicon secured 12 ANDA and 1 NDA approvals, highlighting its robust R&D capabilities and expanding product portfolio.

(Disclaimer: The above article is meant for informational purposes only, and should not be considered as any investment advice. ET NOW DIGITAL suggests its readers/audience to consult their financial advisors before making any money related decisions.)

End of article